ENO2 (Enolase 2) encodes neuron-specific enolase (NSE), a glycolytic enzyme specifically expressed in neurons and neuroendocrine cells. It is a key marker for neuronal injury and has been extensively studied as a biomarker for neurodegenerative diseases and traumatic brain injury.
| Attribute |
Value |
| Gene Symbol |
ENO2 |
| Full Name |
Enolase 2 (Neuron-Specific Enolase) |
| Chromosomal Location |
12p13.31 |
| NCBI Gene ID |
2023 |
| Ensembl ID |
ENSG00000164776 |
| UniProt ID |
P09104 |
| Associated Diseases |
Alzheimer's disease, Parkinson's disease, traumatic brain injury, small cell lung cancer |
ENO2 encodes neuron-specific enolase (NSE), also known as gamma-enolase, which catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolytic pathway. Unlike other enolases (ENO1, ENO3), ENO2 is specifically expressed in:
- Neurons — particularly in the cytoplasm and synaptic vesicles
- Neuroendocrine cells — adrenal medulla, pituitary, pancreatic islets
- Certain tumor cells — especially neuroendocrine tumors
Beyond glycolysis, NSE has been implicated in:
- Neuronal development — differentiation and survival
- Synaptic transmission — may modulate neurotransmitter release
- Stress response — protective effects under oxidative stress
- Cell signaling — interactions with various neuronal proteins
ENO2 is highly expressed in:
- Cerebral cortex (layer 5 pyramidal neurons)
- Hippocampus (CA1-CA3 pyramidal cells)
- Cerebellum (Purkinje cells)
- Substantia nigra (dopaminergic neurons)
- Brainstem nuclei
- Elevated NSE levels in cerebrospinal fluid (CSF) of AD patients
- Correlates with cognitive decline and disease progression
- May reflect neuronal loss and synaptic dysfunction
- Increased NSE in CSF of PD patients
- Associated with disease severity
- Potential biomarker for dopaminergic neuron degeneration
- NSE is a well-established biomarker for neuronal damage
- Serum NSE levels correlate with injury severity
- Used clinically for prognosis
- Small cell lung carcinoma (SCLC) — classic marker
- Neuroblastoma
- Pancreatic neuroendocrine tumors
NSE is used clinically as:
- Serum biomarker for neuronal injury
- CSF biomarker for neurodegenerative diseases
- Tumor marker for neuroendocrine tumors
- Prognostic marker for TBI outcome
- NSE-targeted immunotherapy for neuroendocrine tumors
- NSE as a drug delivery target
- Inhibitors for metabolic manipulation in cancer
- Neuron-specific enolase: a therapeutic target in neurodegenerative diseases
- Neuron-specific enolase as a biomarker for Alzheimer's disease
- Cerebrospinal fluid NSE in Parkinson's disease
- Neuron-specific enolase in traumatic brain injury